References
- Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. (2008). An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 24:1529–1538.
- Kodimuthali A, Jabaris SSL, Pal M. (2008). Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. ;J Med Chem; 51:5471–5489.
- Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, Blease K, Leisten J, Shirley MA, Tang Y, Babusis DM, Chen R, Stirling D, Muller GW. (2009). Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 52:1522–1524.
- McHugh SM, Rowland TL. (1997). Thalidomide and derivatives: immunological investigations of tumour necrosis factor-α (TNF-α) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 110:151–154.
- Papp K, Bolduc C, Rohane P, Sutherland D, Jones M, Hu A, Zeldis J, Thaci D, Kaufmann R. (2008). A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis [abstract]. J Amer Acad Dermatol 58, AB3.
- Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI. (2010). Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159:842–855.
- Van der Mey M, Hatzelmann A, Van Klink GP, Van der Laan IJ, Sterk GJ, Thibaut U, Ulrich WR, Timmerman H. (2001). Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones. J Med Chem 44:2523–2535.
- Wu A, Rohane P, Patin J, Laskin O. (2006). Effects of ketoconazole on the pharmacokinetics of CC10004 in health subjects [abstract]. J Clin Pharm: ACCP Annual Meeting Proceedings, 46:1095.